PSNL
Personalis, Inc. Common Stock
stockNASDAQ
personalis is a genome-scale diagnostics company with a mission to pioneer genome guided medicine. our priority is to obtain the most accurate genetic data from each sample, and then to draw the most reliable medically-focused conclusions from these. our tests are based on whole human genome and exome sequencing, conducted in our state-of-the art laboratory. we analyze results utilizing proprietary databases, advanced human reference sequences, and sophisticated algorithms. personalis genome services provides academic, pharmaceutical, and biotech researchers an accurate and comprehensive end-to-end human genome sequencing and analysis solution. our services support researchers engaging in large case-control and family-based genome studies of complex or mendelian diseases and traits, pharmacogenomics, and cancer.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 16.32 | 2026-09-28 | -0.21% | 0.800 |
| 1M | 17.20 | 2026-09-04 | -5.32% | 0.280 |
| 3M | 14.34 | 2026-07-06 | +13.56% | 1.334 |
| 6M | 6.58 | 2026-04-06 | +147.49% | 2.181 |
| 1Y | 7.20 | 2025-10-06 | +126.18% | 2.764 |
| 2Y | 5.19 | 2024-10-04 | +213.78% | — |
| 5Y | 17.91 | 2021-10-05 | -9.07% | 2.253 |
Personalis, Inc. Common Stock (NASDAQ:PSNL) stock price today is $16.29, and today's volume is 1,139,121. PSNL is up 0.711% today. The 30 day average volume is 2.58M. PSNL market cap is $1.74B with 106.80M shares outstanding.